Loxoprofen

From Wikipedia, the free encyclopedia


Loxoprofen
Systematic (IUPAC) name
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
Identifiers
CAS number	68767-14-6
ATC code	M01AE
PubChem	3965
Chemical data
Formula	C₁₅H₁₈O₃
Mol. mass	246.302 g/mol 304.314 g/mol (sodium salt)
Pharmacokinetic data
Bioavailability	?
Protein binding	97%
Metabolism	Hepatic glucuronidation
Half life	75 minutes
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	?
Legal status	Red Stripe (Brazil)
Routes	Oral, transdermal

Loxoprofen (INN) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group. It is marketed in Brazil, Mexico and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin®, and in Argentina as Oxeno®. It is available in these countries for oral administration, and a transdermal preparation was recently approved for sale in Japan.

[edit] Pharmacokinetics

Loxoprofen is a prodrug. It is quickly converted to its active trans-alcohol metabolite following oral administration, and reaches its peak plasma concentration within 30 to 50 minutes.

[edit] Mechanism of action

As most NSAIDs, loxoprofen is a non-selective cyclooxygenase inhibitor, and works by reducing the synthesis of prostaglandins from arachidonic acid.

[edit] Drug interactions

Loxoprofen should not be administered concomitantly with second-generation quinolone antibiotics such as ciprofloxacin and norfloxacin, as it increases their inhibition of GABA and this may cause seizures. It may also increase the plasma concentration of warfarin, methotrexate, sulfonylurea derivatives and lithium salts, so care should be taken when loxoprofen is administered to patients taking any of these drugs.